Evidence map›Paper›PMID 22975656›Full record

ArticleEye (London, England)2012

Comparative evaluation of lymphatic vessels in primary versus recurrent pterygium.

S Ling, Q Li, H Lin, W Li, T Wang, H Ye, J Yang, X Jia, Y Sun

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Eye (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2015
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Recurrent Pterygium: A Review.Journal of current ophthalmology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

S LingDepartment of Ophthalmology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. lingshiqi123@163.com
Q Li
H Lin
W Li
T Wang
H Ye
J Yang
X Jia
Y Sun
Guangzhou Medical University · CNGuangzhou Women and Children Medical Center · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare lymphangiogenesis in primary versus recurrent pterygium.

methodsTissues from 88 excised primary and 34 recurrent pterygia were evaluated, and tissues from 7 nasal epibulbar conjunctivae segments were used as controls. The lymph-vascular area (LVA), lymph-microvascular density (LMD), and lymph-vascular luminal diameter (LVL) were examined and compared between the primary and recurrent pterygia. In addition, the expression of VEGF-A and VEGF-C in the primary and recurrent pterygia were determined by ELISA and real-time PCR. The relationships between the mRNA level and LVA, LMD, and LVL were clarified.

resultsAlthough there was no significant difference in quantification of LVL between primary and recurrent pterygia, the quantification of LVA and LMD in recurrent pterygia dramatically increased in comparison with primary pterygia (both P-values <0.01). Compared with primary pterygia, the VEGF-A and VEGF-C mRNA levels were up-regulated significantly in recurrent pterygia (both P-values <0.05). There was a significant relationship between VEGF-C mRNA and LVA, LMD, and LVL, while VEGF-A mRNA was only closely correlated with LMD in recurrent pterygia.

conclusionsLymphangiogenesis develops in recurrent pterygium, for which transient up-regulation of VEGF-C might be responsible.

Indexed as

LymphangiogenesisEnzyme-Linked Immunosorbent AssayFemaleHumansLymphatic VesselsMaleMiddle AgedOphthalmologic Surgical ProceduresPterygiumReal-Time Polymerase Chain ReactionRecurrenceRNA, MessengerVascular Endothelial Growth Factor AVascular Endothelial Growth Factor CRNA, MessengerVascular Endothelial Growth Factor AVascular Endothelial Growth Factor CVEGFA protein, human

Identifiers

PMID22975656
PMCPMC3496107
OpenAlexW2012290478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.